MedTrace Logo

Vaccination of Children Following Allogeneic Stem Cell Transplantation

NCT00169728 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2012-06-07

No results posted yet for this study

Summary

The purpose of this study is to determine the immunogenicity and tolerability of the DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate vaccine Prevenar in pediatric recipients of allogeneic haematopoietic stem cell transplantation.

Conditions

  • Allogeneic Haematopoietic Stem Cell Transplantation

Interventions

BIOLOGICAL

DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa

BIOLOGICAL

heptavalent pneumococcal conjugate vaccine, Prevenar

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Dagmar Dilloo, MD, PhD · University Hospital Duesseldorf, Department of Pediatric Oncolgy, Hematolgy and Immunology

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2006-06-30
Completion
2006-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169728 on ClinicalTrials.gov